The antidepressant Wellbutrin has been a lucrative drug for its manufacturer, GlaxoSmithKline LLC. But federal prosecutors claim that the company tried to expand the market for the medication by recommending it for unapproved uses. So far, the only person who’s been charged in the case is a former in-house lawyer. That’s led some observers to wonder whether prosecutors hope to pressure the attorney into identifying other Glaxo officials who promoted off-label uses of Wellbutrin.
Lauren Stevens, a former associate general counsel who worked for Glaxo in Durham, North Carolina, was indicted on November 9. She was charged with one count of obstructing an official proceeding, one count of concealing and falsifying documents in order to influence a federal agency, and five counts of making false statements to the Food and Drug Administration. She faces a maximum penalty of 20 years in jail on the obstruction change, and five years on each of the remaining counts.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
